Market Overview:
Antibacterial drugs are substances that can destroy or inhibit the growth of microorganisms such as bacteria. Antibacterial drugs are often termed antibiotics and are widely used to prevent and treat infectious diseases. Various classes of these drugs have been developed according to the microorganism to be checked. The increasing prevalence of infectious diseases drives the antibacterial drugs market.
Market Size and Growth Rate:
The global antibacterial drugs market reached USD 43,857.4 million in 2022 and is projected to witness lucrative growth by reaching up to USD 63,326.8 million by 2030. The global antibacterial drugs market is expected to exhibit a CAGR of 4.8% during the forecast period (2023-2030).
Download a Free PDF Sample – Click Here
Market Drivers:
The antibacterial drugs market is expected to witness significant growth over the forecast period, owing to the increasing focus of market players on gaining product approvals from regulatory bodies.
For instance, in June 2021, Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved the company’s supplemental new drug application (sNDA) for the oral-only dosing regimen of NUZYRA for the treatment of adults with community-acquired bacterial pneumonia (CABP).
Market Restraints:
The high cost of vaccine development is projected to stifle market expansion throughout the forecast period.
For example, on June 22, 2021, a scientific publication, BMJ, released an article regarding the high cost of vaccination. The Centers for Disease Control and Prevention (CDC) bought bulk vaccination via agreements for the 2020-2021 flu season. The CDC purchased seven million doses directly from manufacturers for US$ 100 million per, a price higher than the previous year, 2020.
Market Opportunities:
The use of combination therapy using numerous antibiotics with distinct modes of action is increasingly being recognized and adopted. The exploration of efficacious combinations that might surmount resistance and optimize treatment results is a very promising area of research.
The field of genetics and diagnostics has made significant progress in the identification of distinct bacterial strains and their varied susceptibilities to antibiotics. Customizing antibiotic therapies according to individual patient characteristics has the potential to enhance effectiveness and mitigate the development of resistance.
Market Segmentation Analysis:
The global antibacterial drugs market is segmented by action type into bacteriostatic and bactericidal; by drug type into beta-lactams, aminoglycosides, tetracyclines, macrolides, sulfonamide, quinolones, others; by route of administration into oral, parenteral, others; by drug mechanism into cell wall synthesis inhibitors, plasma membrane inhibitors, protein synthesis inhibitors, nucleic acid synthesis inhibitors, others; by distribution into hospital pharmacies, retail pharmacies, online pharmacies.
By Drug Type: The beta-lactams segment accounts for the largest market Share.
In 2022, the beta-lactams sector had the largest market share, making for over 40.3% of the antibacterial medication market. Since β-Lactam antibiotics are among the most often prescribed antibiotic classes for antibacterial therapy, the sector benefits from this. By inhibiting PBPs, which are necessary for cross-linking during the development of cell walls, they limit the growth of bacteria.
In addition, pharmaceutical firms with promising pipelines and recent FDA approvals are anticipated to propel market expansion throughout the projection period. For example, the Indian business Alkem introduced Zidavi, a unique combination of ceftazidime and avibactam, on January 30, 2023. The IDSA and ICMR advise using it as the first line of therapy for pyelonephritis and other CRE infections brought on by KPC and OXA-48, as well as for KPC-producing Klebsiella Pneumoniae Carbapenemase (KPC).
For more detailed information, click here
Global Antibacterial Drugs Market Geographical Analysis:
The global antibacterial drugs market is analyzed across North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa.
North America holds a dominant position in the global antibacterial drugs market.
North America is estimated to hold around 36% of the total market share throughout the forecast period, owing to the increased antibiotic resistance, government initiatives, and increased regional FDA approvals.
For instance, in January 2023, Juno Pharmaceuticals Canada received approval from Health Canada to import Amoxicillin powder for oral suspension Amoxicillin. This approval helps to relieve the current nationwide shortage of critical antibiotic products. The U.S. and Canada are experiencing a nationwide shortage of antibiotics. Amoxicillin oral suspension is one of the most commonly prescribed antibiotics for children to treat particular bacterial infections.
Key Developments
- On February 2, 2023, Shionogi & Co. and its European subsidiary, Shionogi B.V., announced that its innovative antibiotic, FETCROJA (cefiderocol), is now available in Denmark for treating infections due to aerobic Gram-negative bacteria in adults (18 years or older) with limited treatment options. This launch in Denmark is an important step in rapidly expanding access to cefiderocol across Europe, with an increasing trend in antibiotic-resistant infections.
- On February 22, 2022, Sistema Group company, Binnopharm Group, acquired Dr. Reddy’s Laboratories’ anti-bacterial medicines underneath the Ciprolet and Levolet brands in Russia, Uzbekistan, and Belarus.
Competitive Landscape:
The major global players in the market include Pfizer Inc., Sanofi S.A., Bayer AG, Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Shionogi & Co., Ltd., Eli Lilly and Company, GlaxoSmithKline Plc, Bristol Myers Squibb Company, Novartis AG, Johnson & Johnson, AbbVie Inc., F. Hoffmann-La Roche AG, Melinta Therapeutics, Otsuka Pharmaceutical Co., Ltd., Insmed, Inc., Basilea Pharmaceutica, R-Pharm, Merck & Co., Inc., and Venatorx Pharmaceuticals among others.
About DataM Intelligence:
DataM Intelligence 4Market Research is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
Trending Topics
Opioid Use Disorder Drugs Market
Antibody Drug Conjugates Market
Androgens and Anabolic Steroids Market
Media Contact
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Send Email
Phone: 08774414866
Address:DATAM INTELLIGENCE 4MARKET RESEARCH LLP Ground floor, DSL Abacus IT Park, Industrial Development Area, Uppal, Hyderabad, Telangana 500039
City: HYDERABAD
State: Telangana
Country: India
Website: https://www.datamintelligence.com/research-report/antibacterial-drugs-market